Cytosorbents Corp
CTSO
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.13M
Close$
$2.35
549.5% upside
Current Fair Value
549.5% upsideUndervalued by 549.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.13 Million |
|---|---|
| Enterprise Value | $47.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.35 |
| Outstanding Shares | 62,806,694 |
Return
| Return on Equity | 2425.17% |
|---|---|
| Return on Assets | -47.98% |
| Return on Invested Capital | -96.91% |
Valuation & Multiples
| P/E Ratio | -1.39 |
|---|---|
| PEG | 0.43 |
| Price to Sales | - |
| Price to Book Ratio | -0.36 |
| Enterprise Value to Revenue | 1.26 |
| Enterprise Value to EBIT | -3.48 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | -35.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$9.80 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$10.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.25%▼ 0.60% |
|---|---|
| Total Invested | $9.32M▼ 13.50% |
| Investors Holding | 50▼ 1.00% |
ESG Score
No data
About Cytosorbents Corp
CEO: Phillip Chan